《睡眠專業人士雜誌》
星期四, 七月 23, 2026
There’s a new name in the study of untreated sleep apnea and the high-tech effort to identify and treat tens of millions of Americans afflicted by it: Primasun. Translating to “first light,” Primasun is the moniker for a joint venture formed in 2018 by Verily, a subsidiary of Alphabet focused […]
ResMed and Verily, an Alphabet company, announced their agreement to form a new joint venture. Combining ResMed’s expertise in sleep apnea and Verily’s advanced health data analytics technologies, the U.S.-based joint venture will study the health and financial impacts of undiagnosed and untreated sleep apnea, and develop software solutions that […]
